An HCP survey-based active surveillance study to assess the safety of fixed dose combination of Levonorgestrel-Ethinyloestradiol (brand name Ovral-L) in the management of primary dysmenorrhea, endometriosis, and abnormal uterine bleeding among Indian females - Protocol# B6261001

Study type

• Study topic:
  Disease /health condition

  Human medicinal product
• Study type:
  Non-interventional study
• Scope of the study:
  Other

  Safety study (incl. comparative)
• If ‘other’, further details on the scope of the study:
  PMS Study
• Data collection methods:
  Primary data collection

Non-interventional study

• Non-interventional study design:
  Cross-sectional

Study drug and medical condition

• Medicinal product name, other:
  Ovral-L (Levonorgestrel 0.15 mg and Ethinyloestradiol 0.03 mg)
• Anatomical Therapeutic Chemical (ATC) code:
  (G03AA07) levonorgestrel and ethinylestradiol

  levonorgestrel and ethinylestradiol
• Medical condition to be studied:
  Dysmenorrhoea

  Endometriosis

  Abnormal uterine bleeding

Study design details

• Study design:
  Surveillance study